We are live on ! Find out more
HITK

Hi-Tech Pharmacal
HITK

Delisted

HITK was delisted on the 16th of April, 2014.

0 hedge funds and large institutions have $0 invested in Hi-Tech Pharmacal in 2026 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 1 → 0 (-1)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $43

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
–
Holders Change
-1
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Huntington National Bank
Huntington National Bank
Ohio
-$43

HITK Hedge Fund Activity: Q3 2026 in Review

0 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in Hi-Tech Pharmacal (HITK) for Q3 2026, worth a combined $0 — down 100% from $43 a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of HITK and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Huntington National Bank, exiting entirely with an estimated $43 sold.

  • 0 institutional investors held Hi-Tech Pharmacal (HITK) as of Q3 2026, down from 1 in Q2 2026.
  • Funds reported $0 of Hi-Tech Pharmacal stock for Q3 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Hi-Tech Pharmacal positions in Q3 2026 and 1 closed out, a net change of -1 holder.
  • The largest Hi-Tech Pharmacal seller in Q3 2026 was Huntington National Bank, an estimated $43 sold.

Based on aggregated 13F filings for Q3 2026.